Alveus Therapeutics

Overview

Our lead product (ALV-001) is the first and only twice-per-year drug/device combination in development for the treatment of type 2 diabetes (T2D). It is a long-acting, subcutaneous implant of a GLP-1. GLP-1 receptor agonists are increasingly used for the treatment of T2D​​, with the global market for GLP-1 agonists exceeding $10B in 2019​.​ 

Globally, an estimated 460 million individuals are affected by T2D​. As with most chronic illnesses, patients have poor adherence to their medication.  Despite the approval of over 45 pills and injections for T2D, the percentage of patients with controlled HbA1c has declined over the last decade​. Only 50% of diabetes patients reach target glucose goals.

​

Phase 3 trials of ALV-001 have been completed successfully, with each trial meeting its primary and secondary endpoints​. However, no regulatory pathways have been pursued ex-US with ALV-001 despite the increasing incidence of T2D globally, significant unmet medical need, and the large commercial potential.